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Abstract
HSV-1 DNA with the green fluorescent protein (GFP) introduced into the UL46
gene was used to investigate the effects of green tea polyphenols on the virus. Two
different green tea extracts have been isolated and modified, EGCG and EGCG-ester.
These extracts with concentration of 12.5, 25, 50, 75 and 100pM were used to determine
its effects on cell morphology, cell proliferation and cell viability. The results indicated
that the maximum non-toxic concentration is 75fiM for both polyphenols. GFP
expression, DAPI DNA stain and Lysosome activation stain were also used to observe
the morphological, and cellular changes in the infected cells. The results suggested that
EGCG-ester treated infected cultures did not show any changes compared with noninfected cells. Each extract was further used to study its effect on HSV1, by plaque
forming unit (PFU) assay and GFP expression. EGCG treated virus had a titer that is ten
fold lower than the control, and EGCG-ester completely inhibited the PFU. Quantitative
study using RT-PCR indicated that EGCG-ester at 75pM inhibited 99.46% of infection
when compared to the control.
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Introduction
Background on Herpes Simplex Virus
The word Herpes was first used by Hippocrates 2,500 years ago to describe skin
diseases. But it was not until 1694, that Richard Morton first described what we now
recognize as Herpes Simplex Virus infection. Finally, in 1921, researchers first
understood that the skin lesions observed from HSV diseases contained infectious
particles and could be passed from human to humans . Out of more than 80
herpesviruses currently known, 8 of them have been identified as potential human
pathogens10.
Herpes simplex virus (HSV) types 1 and 2 belong to the family Herpesviridae,
subfamily Alphaherpesviridae, and the genus Simplexvirus. HSV1 and 2 have been
constant threats to the human populations around the world and are among the most
common infectious diseases in humans35, 38. During the course of one’s life, there is a
high percentage of chance that one will either become infected with HSV1 or HSV2 and
or will meet someone who has either virus. It is believed that when life started on earth,
there was only one Herpes simplex virus and this virus infected monkeys and the great
apes both orally and or sexually. Since monkeys often mix oral and genitalia secretions, it
was common to transfer viral particles from one area to another. When the Herpes virus
developed a way to infect humans, the virus was forced to adapt to changes in personal
and sexual behavior. Given that humans have a more erect posture compared to monkeys,
it became much more difficult to mix oral and genital secretions, thus allowing evolution
to take place and giving rise to two different but very related viruses36. Since then, HSV-
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1 and HSV-2 have coevolved with the human population, and have successfully created a
variety of ways to overpass its host immune system35.

HSV Demographics
The prevalence of HSV infections varies between countries, within regions within
o
a country, an even within subgroups of populations within a region . In the United States,
17% of individuals, ages 1 4 - 4 9 were seropositive for HSV-2 between 1999 and 2004.
These data represent a slight decrease from 1988 - 1994 (21%). The percentage of
individuals in the same age groups and during the same time periods who were
seropositive for HSV-1 also declined (57.7% from 62%). However, this decline was
accompanied by an increase in genital infections caused by HSV-1 .
The risk of acquiring HSV infections increases with several factors such as older
age, lower socioeconomic status, poor education, and high number of sexual partners10.
In the United States, half a million people show new symptoms of HSV infections each
year and the number of first time reported cases keeps increasing every year (fig .l ) 34.
Due to the seriousness of the diseases caused by both HSV1 and 2, controlling HSV
spread and the number of people infected every year is considered a significant public
health concern

.
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Figure 1. Number of People Reporting First Case of Genital Herpes at Doctor’s Offices Within the United
States34.

The Impact of HSV to Human Life
Frequent HSV outbreaks cause discomfort and have a major psychological and
social impact in infected individuals. Those infected by HSV are often concerned about
passing on the virus to eventual partners as well as how they are seen by the outside
world. This in turn can have a negative impact in their social lives and can cause an array
of emotional reactions. Although most HSV infections are asymptomatic, when
symptoms do appear, lesions are painful, recurrent, and ulcerative ’ . HSV-1 can cause
cold sores and lesions of the mouth and lip, as well as herpes keratitis, a leading cause of
corneal blindness in the United States. HSV-1 has also emerged as a leading inducer of
genital herpes in developing countries.

HSV-2 is the source of most cases of genital

herpes, and can, in rare cases, cause encephalitis36,38. Thus, the diseases caused by HSV
infections can have a major impact in one’s life and are often the cause of great turmoil.
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HSV Structure
HSV viruses measure approximately 200nm in diameter. HSV1 and 2 are
enveloped, double stranded DNA viruses of about 152Kb in length, consisting of two
segments of DNA, known as unique long (Ul) and unique short (Us) regions '. The virion
consists of 3 major structures (fig.2); an outer portion called the envelope, which includes
11 glycoproteins (gB gC, gD, gE, gG, gH, gl, gJ, gK, gL, gM), a tegument layer
composed of 15 proteins, and an icosahedral capsid enclosing the viral DNA as well as 4
structural proteins n ’13,42.

Figure 2. HSV Structure47

HSV Life Cycle
As soon as a person is exposed to HSV, a critical series of events within cellular,
molecular and immune system biology takes place. Several glycoproteins located on the
virus envelope are responsible for cell recognition, cell fusion, and eventually cell entry

35

37. The first contact of HSV with its host cell is by binding to heparin sulfate chains
contained on the cell surface proteoglycans. The viral glycoproteins B and C assist this
binding reaction as glycoprotein D is recruited to bind to one the host cell receptors. Once
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glycoprotein D binds to the cell receptor, glycoproteins B, H and L form a fusion
complex along with glycoprotein D and the cell receptor. This fusion complex is what
allows the virion’s plasma membrane to fuse to the host cell plasma membrane and
subsequently viral nucleocapsid and tegument entry. Consequently, although
glycoprotein D is essential for cell recognition and receptor binding, all five
glycoproteins are needed for successful virus adsorption and fusion' ’ .
When a short lysine-rich region (KPKKNKKPK) within glycoprotein B of HSV1 was removed in an experiment with Vero cells, heparin sulfate could not be bound by
the receptors18. Although glycoproteins B and C are not required during the first binding
at heparan sulfate chains, they do make the process more efficient. Thus, not only gD, but
also this lysine-rich region within gB seems to be indispensable for competent viral entry
into the host cell5,37.
Glycoprotein D recognizes and may bind to one of several host receptors. These
include, HVEM (Herpesvirus entry mediator), a member of the TNF-receptor family;
nectin- 1 or nectin-2, members of the immunoglobulin superfamily; and locations on the
cell surface made by the reaction of heparin sulfate and 3-O-sulfotransferases ’ ’ . The
structure of HSV -1 glycoprotein D has been obtained by x-ray crystallography, and
several amino acid residues within gD were seen to be critical for the binding of the
receptors HVEM and nectin-15’20,41. HSV-1 and HSV-2 glycoprotein D have been shown
to contain 82% amino acid similarity. Thus, it is believed that they posses the same or
similar functionality35.
Once inside the cell, HSV will take over the cellular transport machinery in order
to have access to the internal cellular compartments. Viral particles move throughout
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different regions of the cytoplasm in an extremely fast manner allowing viral components
to reach their destinations in a very efficient way42. The viral particles are sent to the
nucleus through the nucleopores where the viral genome will enter and viral transcription
and replication will begin. HSV uses microtubules to travel by retrograde transport to the
nucleus with the help of the dynein motor system3,13,36. Being able to enter the nucleus is
essential for viral transcription, translation, replication, and packaging of the DNA into
progeny nucleocapsids (fig.3). Interestingly, in flat cells such as Vero cells, the process of
transporting viral particles through the usage of microtubules may not be necessary in
order to achieve a successful infection. Vero cells may make use of diffusion to transport
the virion to the nucleus24.
HSV-1 and HSV-2 infect epithelial cells during lytic infection and move to
sensory neurons in latent infections. During the latent infection, viruses stay in a dormant
state within nerve cells until they are triggered into the lytic cycle17,36. This allows HSV
to permanently survive and replicate for the lifetime of the HSV infected patient17,44. For
the virus to become latent, viral particles have to travel from nerve axons at the initial site
of infection to the sensory ganglia3. The latently infected nerve cells do not replicate
HSV’s DNA, but they make mRNA of a short sequence of the genome known as the
latency associated transcript (LAT). A study done in which this sequence was removed
showed that viruses were not able to cause recurrent infections .
These latently infected cells may be unreactive for a long period of time, but can
reactivate at anytime during one’s life course. Currently, it is not known what is the cause
of virus reactivation, but there are several factors that may be associated with
reactivation, such as stress, heat, cold, ultraviolet light, emotional responses, and pituitary
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or adrenal hormones. When the virus is reactivated, the viral genome travels by
anterograde transport in axons, to the epithelium where, viral replication will occur10,35.
Although the only known natural host for HSV infection is humans, cultured cells
from a variety of different animals, such as Vero cells from green monkey kidney cells,
can also be infected by HSV in the laboratory11. In vitro experiments with HSV virions
do not involve the immune system of an animal, allowing the virus to infect cells
efficiently. Thus, several cells contain at least one of the receptors necessary for viral
entry by the envelope glycoprotein gD of HSV .

Figure 3. HSV Life Cycle46
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HSV Transmission and Diagnoses
Transmission of HSV infection is done by intimate contact and the exchange of
body fluids containing the virus. The virus enters the host through a lesion in an infected
person and infects another who has had close contact with the infected person. Even
when there are no apparent symptoms, the infected individual may be shedding the
virus21. People who have been infected with HSV are estimated to be unknowingly
spreading the virus 1 day in every 20 days .
In immunocompromised hosts and newborns, the risk of transmitting HSV is even
greater, leading to eventual fatalities4. The great majority of HSV-2 cases are
misdiagnosed, contributing to the spread of the disease and the further discomfort of the
patient. Because symptoms are not always present, a clinical examination of the patient
as the only form of analysis is not sufficient. Laboratory tests need to be conducted in
o
order to have a more accurate evaluation of an infected individual . There are several
procedures currently done to diagnose HSV. Isolation of HSV in tissue culture is the
preferred diagnostic study, but the use of PCR to amplify HSV DNA in the cerebrospinal
fluid is a faster way to obtain results. Samples can also be analyzed using
immunohistochemical methods for the detection of viral proteins ’ . There is no cure
for the disease caused by HSV infections, thus by correctly diagnosing an infection, one
is able to educate and encourage a patient to contribute to the control of HSV .

Treatment of HSV
The current antiviral drugs of preference for the treatment of oral or genital HSV
infections are acyclovir (Zovirax, Glaxo SmithKline, Research Triangle Park, NC),
valacyclovir (Valtrex, Glaxo SmithKline, Research Triangle Park, NC), penciclovir
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(Denavir, Novaris Pharma GmbH, Wehr, Germany), and famiciclovir (Famvir, Novartis
Pharmaceuticals Corporation, East Hanover, NJ). These drugs are often given orally for 7
to 10 days. Both valacyclovir and famciclovir break down in the body into active forms
of the medicine (acyclovir and penciclovir). By being analogs of nucleosides, these drugs
are able to shut off viral replication4,10,23.
The HSV thymine kinase phosphorylates acyclovir, and the host cell further
phosphorylates it resulting in an active acyclovir triphosphate. Active acyclovir can then
inhibit viral DNA polymerase, preventing viral DNA elongation. The problem with
using these drugs is that they are efficient only until HSV begins to alter its thymine
kinase and becomes resistant to acyclovir and the other drugs that work as analogs of
nucleosides12,19.
The mode of action of famiciclovir is also by inhibiting viral DNA polymerase in
a process similar to acyclovir, although with less efficacy. Famiciclovir is able to obtain
higher concentrations within cells and has a longer-half life compared to acyclovir. It can
also be given less frequently than acyclovir. Lastly, Cidofovir, an acyclic nucleoside 5’monophosphate, is phosphorylated by the host cell kinases and is able to inhibit the viral
DNA polymerase in this manner. HSV resistance to cidofovir may also arise when the
DNA polymerase gene is mutated4,36. Because of the great resistance that arises from
taking these different drugs, new and more effective medications need to be developed in
order to prevent the shedding of HSV ~.

The Link Between HSV and HIV
Although HSV-2 is the most common way of acquiring genital herpes, HSV-1 has
also been linked to genital herpes in developing countries38. Genital herpes increases the
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risk of sexually acquired HIV infections, and is therefore considered a serious public
health concern27,39. Lesions and or blisters in the skin caused when the HSV lytic cycle is
active allows for an easy route of HIV transmission during sexual activity. When a
person is suffering from HSV outbreaks, white blood cells travel to the site of infection,
but these white blood cells are in turn an easy means for HIV to gain access into another
person’s body34,41. In a study conducted with 224 couples in which only one of the
partners was HIV seropositive, it was established that HIV RNA is often seen in HSV
lesions. The scientists also noticed that when HSV is reactivated, the possibility of HIV
viral loads increasing is immense. Lastly, when human CD4 cells are coinfected with
9A

both HSV and HIV, replication of HIV is greatly enhanced .
Unfortunately, anti-HSV drugs currently on the market have not proven to be
effective against both HSV and HIV. Thus, people with Herpes have yet no choice but to
protect themselves at all times, until a better and more efficient antiviral topical
application is made10,38.

Green Tea and the Search for Microbicides
Topical microbicides are currently being researched and tested for intravaginal
usage against HSV and other sexually transmitted diseases. Scientists have been trying to
come up with an effective vaccine against HSV as well, but it has proven to be extremely
challenging since HSV establishes latency and an infection may arise even if the immune
system becomes activated2,36. As a result of the emergence of drug resistance and the
absence of an effective HSV vaccine, new antiviral drugs need to be developed. More
importantly, HSV infection could be significantly reduced if effective agents for
prevention are developed.
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Green tea has been an important food in the life of Chinese people for decades
now. Green tea consumption flourished in China after it was said to cure the people in the
troops of General Zhu Ge Liang (181-234 A.D.). A few decades later, green tea became
an essential part of the Chinese culture. In recent years, green tea has gained great
support through scientific discoveries, and scientists have now started to test the benefits
of green tea in trying to combat different types of illnesses. Diseases such as cancer,
diabetes, obesity, influenza, and Herpes Simplex Viral Infections, once thought
impossible to treat and or cure, have been given hope with the advance of research and
n

the use of innovative compounds such as green tea polyphenols . Therefore, there is a
huge interest in its antimicrobial and antiviral potential. Green tea polyphenols have been
shown to possess antimicrobial properties, including HSV, and can thus be a good
candidate in HSV prevention16.

Epigallocatechin gallate (EGCG)
Green tea is made from the Camellia sinensis plant. It is rich in catechin
polyphenols, in particular, epigallocatechin gallate (EGCG). EGCG has not been found in
any other plant, but is the main catechin found in tea . EGCG is on the FDA’s list as a
safe consumption product23. EGCG has received much attention due to its antiviral,
antimicrobial, and anticancer activities. Scientists have shown that EGCG is able to
inhibit HIV by inhibiting the binding of an envelope glycoprotein (gpl20) to its receptor
(CD4) 43. Influenza is also inhibited by EGCG through interaction with the
hemagglutinin envelope glycoprotein, which may lead to an alteration in the envelope
structure34. In addition, EGCG also inhibits hepatitis B by interfering with viral DNA
synthesis and thus stopping viral replication13.
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While green tea has also been the subject of several other studies, virologists
have tried to focus on whether it has the ability to inhibit different viral infections. In a
study conducted with Vero cells and both HSV-1 and HSV-2, researchers concluded that
EGCG successfully inhibited HSV infection in a concentration dependent manner. Other
green tea catechins were also tested, but only EGCG produced the inhibitory effect.
Results also showed that treating Vero cells treated with EGCG following adsorption and
entry of HSV-1 does not inhibit the viral production. EGCG has to be applied before the
virus is adsorbed in order for an effect to be seen. Also, after treatment of Vero cells with
EGCG, the envelope of HSV virions was damaged. As a result, EGCG seemed to have a
direct effect on the inhibition of HSV16.
When ECGC treated HSV-1 and non-treated HSV-1 were immunogold labeled
with antibodies against gB, gD, and a capsid protein, there was a 30% and a 40% drop in
the treated compared to untreated virions. Therefore, once the virus is treated with EGCG
its envelope glycoproteins have a decreased ability to bind to the monoclonal
antibodies16.
There is no doubt now that the EGCG compound in green tea inhibits HSV, but a
problem one would face when preparing a topical application with EGCG is that it is
highly unstable and oxidizes very quickly, losing its antiviral abilities long before one
would be able to apply it. Most of the studies done with EGCG, have to be done with
freshly prepared EGCG, otherwise it looses it potent antiviral activity ’ . Also, since
EGCG is water soluble, one would not be able to benefit from it as a topical application.
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Epigallocatechin gallate-ester (EGCG-ester)
However, it has been proposed that fatty acid esters of the polyphenols (EGCGester) can be used as an effective antiviral agent as an ingredient in lipophilic
preparations for HSV prevention22. Lipid esters of EGCG can be formed either
enzymatically or chemically6. Data generated from experiments using influenza virus
showed that the esters of EGCG are 24 times more effective to inhibit the infection and
inactivate influenza virus. Since a high concentration of EGCG is needed in order for an
antiviral effect to be seen in influenza, researchers thought of a way to increase its lipid
membrane permeability, its chemical stability, and slow down its metabolism Thus, they
introduced an ester chain to EGCG and were able to greatly enhance its anti-influenza
virus activity22. The same procedure can potentially be applied to HSV.
Both HSV 1 and HSV2 pose a serious threat to human populations around the
world, and the number of people infected with the disease each year has been shown to
increase. The therapeutic usage of EGCG has been suggested previously, but EGCG in its
original form would not be adequate to be implemented in a topical application without
rapid oxidation and lost of antiviral activity. EGCG-ester, on the other hand, would be an
ideal candidate for this purpose.

EGCG-Esterification
The structure of EGCG-ester was purified previously by a team of researchers in
China. This was accomplished from a catalytic esterification between green tea
polyphenols and Ci6-fatty acid. The esterification was obtained by mixing 4 grams of
green tea polyphenols and 6.5 grams of hexadecanoyl chloride. Next, 50mLs of ethyl
acetate and a catalyst at 40°C were added to the mixture. After 3 hours of stirring, the
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solution was washed three times with 30mLs of deionized water. The organic layer was
then allowed to evaporate and further dried by using a vacuum at 40°C. This resulted in
8.7g of powder product. The reaction can be seen in figure 46.

Figure 4. A likely Esterification Between GTP and Hexadecanoyl Chloride 6.

Next, high current chromatography separation was used to purify the EGCG-ester
product. A two-phase solvent composed of (1:1) n-hexane-ethyl acetate-methanol-water
was used in the separation column. Five grams of EGCG-ester was dissolved in 50mL of
the upper phase solution. After purification and HPLC analysis, it was seen that EGCGester was successfully purified. The structure of EGCG acyl-derivative can be seen in
figure 56.
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GHSV-UL46
With a green fluorescence protein tagged HSV, it is possible to study the HSV
viral life cycle, and study potential effects of lipophilic tea polyphenol on in vitro HSV
infections42. EGCG-ester may well be a novel and more effective form of EGCG for
topical applications. If ester-modified EGCG is proven to have similar or better results
against HSV infections, future animal and human studies can then be conducted toward a
stable, and effective topical application to prevent human herpes simplex viral infection.
Sexually transmitted HSV infects the host cell very quickly; therefore, an efficient
antiviral drug needs to be made in order to inhibit HSV prior to the initial viral
infection16.
A HSV 1 virus model has been modified by a team of researchers at Washington
University School of Medicine. A green fluorescent protein was attached to the viral gene
UL46 that encodes tegument protein VP 11/12. A schematic representation can be seen in
figure 6. The GFP sequence was added to the UL46 gene by using homologous
recombination vectors and primers designed to amplify the desired sequences4-.
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Figure 6. Schematic of How GFP was Introduced to the Gene UL46 of HSV142.

Research Proposal
The objectives of this research are as follows:

I. Identify and analyze any effect EGCG or ECGC-ester may have on in vitro
cultures of VERO cells (green monkey kidney cells) and later on A549 cells.
II. Identify, analyze and compare any effects EGCG or EGCG-ester may have on
HSV1 infections.
III. To provide insight into molecular mechanisms of EGCG and EGCG-ester in
HSV1.
Successful completion of this project should elucidate the potential inhibitory effect of
EGCG and EGCG-ester may have against H SV 1. The results of this in vitro study will be
of great significance as they may be used to develop a topical application against HSV
infections.
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Materials and Methods
Cells Culture Maintenance
Vero cells were purchased from ATCC (Manassas, VA) and were cultured in T25
flasks containing Dulbecco Minimal Essential Media (DMEM) with 5% Fetal Bovine
Serum (FBS) and lug/mL gentamycin at 37°C and 5% C 0 2 until confluent. Cell growth
was carefully monitored using an ACCU-SCOPE phase contrast microscope with
attached Micrometries digital camera and Micrometric SE Premium software. To
maintain the cultures, confluent monolayers of Vero cells were trypsinized with 500pL of
Trypsin/ EDTA for 5 minutes. 4.5mLs of media was then added to the T-25 flask and
cells were subcultured into 6 well plates or other T-25 flasks and incubated until
confluent.

HSV1-UL46 Virus Maintenance
HSV1-UL46 virus was purchased from ATCC (Manassas, VA). Passage of virus was
done in T-25 flasks and cells were allowed to reach complete cytopathic effect (CPE).
The media was then collected into 15mLs tornado tubes and it was centrifuged at
lOOOrpm for 10 minutes to remove cellular debris. The supernatant containing virus was
then kept under -80°C until needed.

Preparation of Green Tea Polyphenols Solutions
Samples of EGCG and EGCG-ester were generously given to our laboratoty by Dr.
Stephen Hsu from the Medical College of Georgia. The two different polyphenols tested
were EGCG and EGCG-ester. The concentration span we used was 12.5, 25, 50, 75, and
lOOpM.
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Cytotoxicity Assay
In the first cytotoxicity experiment, Vero cells were plated in 6 well plates with
different concentrations (12.5, 25, 50, 75, lOOpM), of EGCG or EGCG-ester. Cells were
studied for morphological and proliferation changes 48hrs later using an ACCU-Scope
3002 microscope with a camera attached.
The next experiment, Vero cells were plated in 6 well plates and after a period of
24 hours, different concentrations (12.5, 25, 50, 75, lOOpM) of EGCG or EGCG-ester
were added to each well respectively. After one hour, the polyphenols were aspirated and
the cells were washed with PBS. Cells were studied for morphological and proliferation
changes 24hrs later using an ACCU-Scope 3002 microscope with a camera attached.

Cell Viability Assay
Vero cells were plated in 6 well plates and after a period of 24 hours different
concentrations of EGCG or EGCG-ester (12.5, 25, 50, 75, lOOpM) were added to each
well, respectively. After one hour, the polyphenols were aspirated and the cells were
washed with PBS. DMEM media was put back into each well and cells were incubated
for 24hrs. Cells were then counted using a hemocytometer and trypan blue which stains
the dead cells blue and leaves the live cells white.

Cell Proliferation Assay
Cell proliferation kit (G5421, Promega Corp.) was used. This is a colorimetric
method for determining cell proliferation. This kit contains a tetrazolium compound and
an electron-coupling reagent (phenazine methosulfate). Only live cells will be able to
bioreduce the tetrazolium compound into soluble formazan. Thus, the amount of
formazan formed and measured at 490nm absorbance is directly proportional to the
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number of live cells. Cells were plated into 96 well plates and after 24 hrs they were
treated with different concentrations (12.5, 25, 50, 75, lOOpM) of polyphenols and
allowed to adsorb for 1 hour. Polyphenols were then aspirateded and lOOpL of fresh
DMEM was added back to each well. 24 hours later, 20pL of the MTS reagent was added
to every lOOpL of cells in media. The plates were incubated at 37°C and 5% CO 2 for 4
hours, and then the absorbance was read using a plate reader.

Viral Titer Study Using Plaque Assay
Vero cells were plated on 6 well plates and allowed to reach confluence. HSV
virions were treated for 1 hour with the respective concentration of polyphenols (12.5, 25,
50, 75, lOOpM) prior to cell infection. Cells were then infected with HSV and allowed to
adsorb for 1 hour. Viruses that had not been absorbed were then aspirated. Plates were
then overlaid with a nutrient medium-containing agar. Plaques were visualized by
staining cells with crystal violet, observed, and counted within 50 hours.

Esherichia coli Ampicillin-Resistant Plasmids w. Green Fluorescent Protein (GFP)
An ampicillin-resistant strain of Esherichia coli was isolated from a pure colony
that was originally grown on Luria Broth (LB) in the presence of ampicillin and Larabinose. The colonies were transferred onto new LB that had been supplemented with
lOOpl of ampicillin and lOOpl of L-arabinose prior to transferring the colonies. The
concentration of ampicillin used was lOOng/mL. The concentration of L-arabinose was
created using serial dilutions and set in a 1:10 ratio to create a solution of 5% percent.

GFP Expression Study Using a Fluorometer
GFP expression was studied in Escherichia coli that contained GFP plasmid, and

Escherichia coli without GFP plasmid. The fluorometer used was a Tuner Digital
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Fluorometer- Model 450. Samples were put into 3mLs of H20 and serial dilutions were
performed from the first 3 mLs of each sample. A standard dilution curve was obtained
from the serial dilutions.
Next, Vero cells were grown on T-75 flasks and allowed to reach confluence.
H SV 1 virions were treated for 3 hours with 75pM of polyphenols prior to cell infection.
Cells were then infected with treated and non-treated HSV 1-UL46 and allowed to adsorb
for 1 hour. Viruses that had not been absorbed were then removed by washing the cells
twice with PBS. The cells were then incubated at 37°C for 12hrs. Cells were then
trypsinized and pelleted. Finally, cells were resuspended with 3mLs of H20 and analyzed
for GFP expression using a fluorometer. 3ml of water was used as the blank sample. The
Gain knob was set to 1000 for higher fluorescence sensitivity.

Fluorescence Microscopy Study
Cells were grown on glass cover slips and allowed to reach confluence. They
were then infected with either control HSV or previously treated HSV for 1 hour. Time
course studies were performed in which the virus was allowed to adsorb for 1 hour and
then aspirated. Cells were washed with PBS and media was added to each well. After a
period of 8, 10 and 12 hours, cells were then fixed with a 1:1 acetone and methanol
solution and visualized under a Zeiss Axiovision fluorescence microscope using
differential interference contrast settings.

DNA Extraction from HSV1 Infected Cells
Cells were grown on 60mm plates and allowed to reach confluency. Cells were
then infected with HSV 1 treated and HSV 1 non-treated for 1 hour at 37°C and 5% CO?.
After absorption time, cells were washed with PBS and media was added to the plates.
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After 12 hours, cells were trypsinized and DNA was extracted using the DNeasy Blood
and Tissue Handbook (Qiagen 2006). DNA concentration was then measured by using a
Nanodrop Specrophotometer.

Polymerase Chain Reaction
Nine sets of primers were designed to prime different regions of the HSV1
genome based on published sequences. Two sets of primers were designed to target
HSV1 glycoprotein D. These include 5 ’-AGACGTCCGGA A AC A ACCCTAC AA-3 ’ for
the forward and 5 ’-ACACAArTCCGCAAAFGACCAGGG-3’for the reverse. The second set
includes 5 -TTG111GTCGTCATAGTGGGCCTC-3’for the forward and
5 ’TGGATCGACGGTATGTGCCAG111-3’ for the reverse. Next, two sets of primers were
designed to target H SV 1 glycoprotein B. They are the following:
5’AGATTCTGCGGTACTGCGArCACT-3’ for the forward and 5’ACGGAACACAAACAAGCACGGArG-3’for the reverse. The second set includes
5,-AGCTGArTArCGCCACCACACrCT3’- for the forward and
5’TGGCGTTGArcrTGTCGArCACCr-3’for the reverse. A third set of primers had been
previously designed and published on the book Herpes Simplex Vims Protocols by S.
Moira Brown and Alasdair R. MacLean. The set includes
5 ’ATTCTCCTCCGACGCCATATCCACCTT-3’ for the forward and 5’AGAAAGCCCCCATTGGCCAGGTAGT-3 ’ for the reverse.
A set of primers was designed to target the Green Fluorescent protein attached to
the UL46 gene of HSV 1. It includes 5 ’-TGACCCTGAAGTTCArCIGCACCA-3’for the
y

forward and 5’-AACTCCAGCAGGACCATGTGAT-3’for the reverse. A second set of
primers designed for the GFP had been previously designed42. It includes 5’-
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GTCAAAGCTTAAGATGGTGAGCAAGG-3’ for the forward and 5’CTTGAAGCTTCTTGTACAGCTCGTCC-3’ for the reverse. Finally, two sets of primers
were designed to target H SV 1 tegument protein V P11/12 that corresponds to the UL46
gene. They are the following: 5 ’-ACCAAGCCnGATGCTCAACTCCA-3 ’ for the forward
and 5’-ACAACACGGTTCCCGAGAG 1 1TGA-3 ’ for the reverse. The second set includes5’ACCAAGCC11GATGCFCAACTCCA-3’ for the forward and
5ACACAACACGGTTCCCGAGAGTTT-3’for the reverse.
The reaction mix included lp L of the extracted DNA, lp L of forward and lp L of
reverse primers, 12.5pL of Master Mix, and 9.5pL of diH 20. The mix was put into PCR
tubes and placed into a Labnet MultiGene II thermal cycler (Labnet International, Edison
NJ). The reaction profile was initial denaturation at 95°C for 2 minutes followed by 30
cycles of denaturation at 95°C for 30 seconds, annealing at 60°C for 1 minute and
extension at 72°C for 30 seconds. The last step included a final extension period at 72°C
for 10 minutes. Once the cycle was over, samples were cooled down to 4° and then stored
at -20°C freezer for future analysis via agarose gel electrophoresis.

Analysis of PCR Products
Polymerase chain reaction products were analyzed and visualized on 1% agarose gels.
Each gel was made by weighing 0.5g of agarose (USB Corporation, Cat No 32802) and
combining it with 50mLs of IX TAE (Tris-Acetate- EDTA) buffer. The mixture was
heated for 1 minute in a microwave until the agarose completely dissolved. The mixture
was then poured into a gel rig and allowed to solidify. A gel comb was used on one end
of the gel in order to produce the wells. Once the gel had solidified samples were loaded
into each well (2pL of 10X loading dye with lOpL of PCR product). A Hi-Lo DNA
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marker was loaded into the first well. The gel was run at 115V for 1 hour. The gel was
then stained with Ethidium Bromide for 15 minutes and washed with water for another 15
minutes. The gel was then analyzed under UV light using Kodak Image Station 440 CF
(Perkin Elmer Life Sciences, Waltham,MA).

Real Time Polymerase Chain Reaction
A set of primer that primes H SV 1 glycoprotein D was designed for use in Real
time polymerase chain reaction. This set includes 5”-CAACCCTACAACCTGACCATC3’ for the forward and 5’TTGTAGGAGCArTCGGTGTAC-3’for the reverse. Each tube
(except the negative controls- no DNA) contained lOpL of Fast SYBR green master mix
(ABI Fast SYBR Green Master Mix), lp L of forward primer, lp L of reverse primer, lp L
of genomic DNA and 6pL of Di IFO. The samples were run on an ABI StepOnePlus
Real-Time PCR System. The Run methods were: a holding stage at 95°C for 5 minutes
followed by 40 cycles of denaturation at 95°C for 1 minute, annealing at 60°C for 1
minute and extension at 72°C for 30 seconds. Next, the melting curve stage included
95°C for 15 seconds, followed by 60°C for 1 minute, and 95°C for 15 seconds.
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Results and Discussion
1. Cytotoxicity Study of EGCG/Vero Cells and EGCG-ester/Vero Cells Without
Removing Polyphenols
In order to determine the proper concentrations of EGCG and EGCG-ester to be
used for treating HS V 1, the effect of polyphenols on the cells were studied. Different
concentrations of EGCG and EGCG-ester (12.5, 25, 50, 75, lOOpM) were evaluated and
both the growth and morphology of the cells were observed at 48hrs. In this experiment,
the polyphenols were added at the same time as the cells were plated and were not
removed subsequently. The results are shown in figures 7 and 8.

EGCG- 48hrs

Figure 7. Microscopic Observation (200X) of Cytotoxicity Study of Vero Cells Treated with Different
Concentrations of EGCG (A) OpM; (B) 12.5pM ;(C) 25pM; (D) 50pM; (E) 75pM; (F) lOOpM.
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EGCG-ester 48hrs

Figure 8. Microscopic Observation (200X) of Cytotoxicity Study of Vero Cells Treated with Different
Concentrations of EGCG-ester (A) OpM; (B) 12.5pM ;(C) 25pM; (D) 50pM; (E) 75pM; (F) lOOpM

Experiments to assess the cytotoxicity of green tea polyphenols for cultured
eukaryotic cells indicate a moderate toxic behavior of these polyphenols in cell cultures.
The results suggest that when EGCG is added to Vero cells, there are no morphological
changes seen in the concentrations used. In the presence of EGCG-ester the maximum
nontoxic concentration was evaluated to be 75pM. At the concentration of lOOpM, cell
morphology is affected to a certain extent.

2. Cytotoxicity Study of EGCG/Vero Cells with Removing the Polyphenols (24hrs):
The effect of different concentrations of EGCG-ester on Vero cells was also
observed at 24 hrs. Since in the procedures for H SV 1 infected cultures, after 1 hr
adsorption, the media and unabsorbed virus are aspirated, it is important to determine the
effect of polyphenols under similar conditions. In this study, Vero cells were plated first
for 24 hours and then different concentrations of EGCG-ester (12.5, 25, 50, 75, lOOpM)
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were added to the cells and allowed to adsorb for 1 hour. EGCG-ester was then aspired,
and cells were observed 24 hours later. The results are shown in figure 9.

Figure 9. Microscopic Observation (100X) of Cytotoxicity Study of Vero Cells Treated with Different
Concentrations of EGCG-ester (A) OpM; (B) 12.5pM; (C) 25pM; (D) 50pM; (E) 75pM; (F) 100pM.

As indicated in figure 9, as the concentration of EGCG-ester is increased, cell
morphology was not greatly affected. This is therefore the method used for subsequent
experiments.

3. Cell Viability Study of EGCG-ester on Vero Cells
The cytotoxicity study indicated that EGCG and EGCG-ester at concentration of
12.5 to 75pM do not change cell morphology. The cell viability was then determined by
using trypan blue and hemacytometer direct cell count to detect the effect of EGCG-ester
on Vero cells. The results are shown in figure 10 and table 1.
As the concentration of EGCG-ester is increased, the percentage of cell death is not
changed. Therefore, the maximum nontoxic concentration, 75pM EGCG-ester, can be
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used to treat H SV 1 and study its inhibitory effects. Figure 11 illustrates a graph of
hemacytometer count of live cells that appear white and dead cells that stain blue.

Figure 10. Cell Viability Studies of Vero Cells Treated with Different Concentrations of EGCG-ester
Live cells
Dead cells

Live cells
Dead cells
% of death

OpM
4.01E+07
1.45E+06
3.60%

12.5pM
2.56E+07
2.70E+06
10%

25pM
2.72E+07
2.95E+06
10%

50pM
2.89E+07
2.90E+06
10%

75pM
2.71E+07
1.70E+06
10%

Table 1. Cell Viability Data of Vero Cells Treated with Different Concentrations of EGCG-ester
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Figure 11. Microscopic Observation under 400X of Vero Cells on a Hemacytometer.
------- ► Live cells
------- Dead cells

4. Cell Titer 96® Aqueous One Solution Cell Proliferation Assay (MTS)
The previous results suggested that EGCG-ester does not show significant effect
on Vero cell cytotoxicity and viability. In this study, cell proliferation was examined
under the same conditions as described before. Each experiment was assayed in
triplicates, and absorbance of this colorimetric assay was recorded at 490nm using a 96
well ELISA plate reader. The results are shown in table and figure 12.

A

M ean

B

EGCG

EGCG

EGCG

EGCG

pEAjrCCr
rrr

12.5uM

25uM
0.616
0.628
0.620
0.621

50uM
0.589
0.632
0.587
0.603

75uM

lOOuM
0.730
0.688
0.677
0.698

0.601
0.615
0.606
0.607
EGCGe s te r
12.5uM

M ean

2

0.652
0.645
0.645
0.647

EGCGe ste r

EGCGe ste r

EGCG-

25uM

50uM

75uM

EGCGe ste r

C ontrol

0.780
0.793
0.752
0.775

C o n tro l

lOOuM

0.642

0.668

0.663

0.582

0.691

0.780

0.647

0.651

0.698

0.689

0.741

0.793

0.574

0.621

0.667

0.687

0.719

0.752

0.621

0.647

0.676

0.653

0.717

0.775

Table 2. Cell Proliferation Data with Mean and Standard deviation of Vero Cells Treated with Different
Concentrations of EGCG and EGCG-Ester (A) EGCG/Vero (B) EGCG-ester/Vero.
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Figure 12. Cell proliferation Studies of Vero Cells Treated with Different Concentrations of EGCG and EGCGester
EGCG/Vero cells- 48hrs
EGCG-ester/Vero cells- 48hrs

The proliferation assay results in table 2 and figure 12 indicate that both EGCG
and EGCG-ester are not inhibiting cell proliferation to a great extent. In comparison to
controls, cells exhibited only a small decrease in levels of 490nm absorbance. This
indicates that most of the cells are inducing high reduction of MTS tetrazolium to
formazan and therefore retain high cell viability. As seen, increases in the concentrations
of EGCG and EGCG-ester up to 75pM do not lead to a significant reduction in cell
proliferation.

5. The Effect of EGCG and EGCG-ester on the Production of HSV1 Particles
Viral titer was determined to study the effect of 50pM of EGCG and EGCG-ester
on the viral particle production by using plaque assay. Serial dilutions of viral lysates

29

were performed from 10 1to 107 and cells were then infected respectively with the
dilutions. Results can be seen in figure 13. In the HSV 1/Vero cells experiment, plaques
were observed from 10"3to 1O'5 viral lysate dilution and the viral titer was 1.25x 106
PFU/ml. In the 50pM EGCG-HSV1/ Vero cells experiment, plaques were only observed
from 1 0 3 to 10'4, and the viral titer was lxlO 5 PFU/ml. Lastly, in the 50pM EGCG-esterHSV 1/Vero cells experiment, there was no plaque formation seen in any of the viral
lysate dilutions. The results are summarized in figure 14, which demonstrates, a 10-fold
decrease when comparing HSV1/ Vero titer to EGCG-HSV 1/Vero titer. It also shows an
even larger decrease in EGCG-ester HSV 1/Vero titer compared to HSV 1/Vero titer. This
indicates that EGCG-ester is more potent in inhibiting HSV 1 when compared to EGCG.
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Figure 13. Plaque Assays of HSV1, HSV1 Treated 50qM EGCG , HSV1 Treated 50jiM EGCG-ester. (A) Titer of
HSVl/Vero (10 3 to 10'7); (B) Titer of 50qM EGCG- HSVl/Vero (10'3 to 10'7); (C) Titer of 50uM EGCG-ester
HSVl/Vero (10"3 to 10 7).
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V IR A L T IT E R
H S V l/ V e r o , E G C G -H S V l/ V e r o , and
E G C G -e ste r H S V 1 / V ero
1.00E+06

1.00E + 04

1.00E+02

1.00E+00
OjjM

50|j M-EGCG

50pM-EGCGe ste r

Polyphenol co n ce n tra tio n s (pM )

Figure 14. Viral Titer Comparison of HSV1, HSV1 Treated 50pM EGCG, HSV1 Treated 50pM EGCG-ester.

In order to obtain the minimum inhibitory concentration of EGCG-ester on HS V 1,
different concentrations (12.5,25,50,75fiM) of EGCG-ester were used at lower dilution of
viral lysate (1 0 1 andlO’2). The results are shown in figure 15. Figure 15(A) shows the
101dilution and 15(B) shows the 10‘2 dilution. The results indicated that as the
concentration of EGCG-ester is increased, HSV1 titer is decreased. As seen in figure 16,
at a concentration of 50pM EGCG-ester and above, the HSV 1 ability to form plaques is
reduced by >99%.
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Figure 15. Viral Titer of HSVl/Vero and Different Concentrations of EGCG-ester HSVl/Vero. (A) HSVl/Vero
and Different Concentrations of EGCG-ester HSVl/Vero at 10'1Dilution. (B) HSVl/Vero and Different
Concentrations of EGCG-ester HSVl/Vero at 10'2Dilution.

V iral T ite r
1.40E + 03

1.31E+03

1.20E + 03
1.00E+03
8.00E+02
6.00E + 02
4.00E + 02
2.00E + 02
0.00E+00
OpM

12.5|JM

25|j M

50|j M

75[j M

E G C G -e ste r co n ce n tra tio n s (|jM)
Figure 16. Viral Titer of HSVl/Vero and Different Concentrations of EGCG-ester-HSVl/Vero
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6. Study of Green Fluorescence Protein Expression in HSVl/Vero Cells and EGCGester-HSVl/Vero Cells
The viral model system used in this study, HSV-GFPUL46, carries a green
fluorescence protein (GFP) tag on the H SV 1 UL46 gene. In this study, a fluorometer was
used to measure the expression of green fluorescence protein in infected Vero cells. In
order to quantitatively determine the GFP expression in cells, a standard dilution curve
was generated with Escherichia coli (E.coli) containing a GFP insert. Escherichia coli
with no GFP insert was also used as a negative control. Serial dilutions of E.coli cultures
were prepared as described in the Materials and Methods section. The results are shown
in table 4 and figure 17.
As seen in the results, a linear dilution curve was successfully generated with
serial diluted cultures of E.coli with GFP. The negative control shows very low readings.
This experiment demonstrated that the use of the fluorometer is appropriate to provide a
quantitative measure for GFP expression.
E c o li+ G F P
1000
541
284
148
75
35
17
8
4
2

E c o li-G F P
22
13
7
4
1
0
0
0
0
0

D ilu t io n s
1/1
1/2
1/4
1/8
1/16
1/32
1/64
1/128
1/356
1/712

Table 4. Fluorometer Data of GFP Expression in E .c o li with a GFP Plasmid Insert and E.coli with no
GFP Plasmid Insert.
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Fluorometry

E.ccli+GFP
E.ccii-GFP

Figure 17. Fluorometer Study of GFP Expression.
[

E .c o li

with GFP plasmid.

^ E .c o li with no GFP plasmid.

This experiment demonstrates that the fluorometer can be used to study and
quantitatively measure GFP expression in both HSVl/Vero cells and EGCG-esterHSVl/Vero cells. In this experiment, Vero cells only, HSVl/Vero cells, and 75pM
EGCG-ester-HSVl/Vero cells were used to quantitatively measure GFP expression. The
results are shown in figure 18.
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Figure 18. Fluorometer Study of HSV1 GFP Expression

Cells only
HSVl/Vero
75uM EGCG-ester HSVl/Vero

As seen, GFP expression is much lower in 75pM-EGCG-ester HSV1/ Vero cells
compared to HSVl/Vero cells. Thus, expression of GFP as part of viral biosynthesis is
decreased when HSV1 is treated with EGCG-ester.

7. Fluorescence Microscopy Observation of HSVl/Vero Cells and EGCG-esterHSVl/Vero Cells
The lytic cycle of HSV1/ Vero cells was observed at 8, 10, 12 hours post
infection to study the molecular changes within the infected cells. HSVl/Vero cells were
used as positive controls and Vero cells were used as negative control. 75pM EGCGester-HSVl/Vero cells were also monitored and compared to controls. GFP-HSV1, DAPI
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stained nucleus and lysosome stain were used to identify cytophatic effects on Vero cells.
The course study was performed in triplicates and the representative fluorescence images
are shown in figures 19-26.
A single cell without HSV1 infection and EGCG-ester treatment are showed in
figure 19. The images are used as a reference to compare to all the treated samples. In
the image with DAPI stained nucleus, there is very smooth margin and no granules are
observed within the nucleus. In the green fluorescence image, there is an obvious green
background, but no green fluorescence particles. In the lysosome stain, although there is a
red background, there are no obvious fluorescence red particles inside the cells.
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Figure 19: Fluorescence Microscopic Observation of Single Vero Cell at 400X. (A) Overlay image of GFP and
DAPI stain; (B) DAPI stain; (C) GFP; (D) Lysosome stain.

Next, uninfected Vero cells in a monolayer without any treatment were observed
under 400X magnification. The images of the phase contrast microscopy, DAPI, GFP,
DAPI+GFP, DAPI+GFP+Lysosome stains and an all stain-overlaid image are shown in
figure 20. Overall, figure 20 provides information of the cell morphology and the
background for all the fluorescence staining.
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Figure 20. Fluorescence Microscopic Observations of Vero Cells Monolayer (400x). (A) Phase contrast; (B)
DAPI stain; (C) GFP; (D) GFP+DAPI; (E) GFP+DAPI+Lysosome (F) Lysosome stain.
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HSVl/Vero cells and EGCG-ester-HSVl/Vero cells were observed 8 hrs post
infection as shown in figure 21. Phase contrast image for HSVl/Vero cells are very
different from EGCG-ester-HSVl/Vero cells. The cell morphology was greatly changed,
indicating lytic viral infection in the HSVl/Vero cells. Cell morphology of EGCG-esterHSVl/Vero is very similar to the cells alone image, illustrated in figure 20. The results
imply that HSV 1 was not able to continue with its lytic cycle when treated with EGCGester.
When staining the HSVl/Vero cells with DAPI stain, there is an obvious
difference in the cell nucleus compared to the EGCG-ester-HSVl/Vero cells. Significant
granulation as well as demargination is only seen in the HSVl/Vero cells, demonstrating
a normal occurrence of viral infection as indicated by the yellow arrow in figure 15(B).
EGCG-ester- HSVl/vero cells still maintained their nuclear integrity and show similar
appearance to the cells only image.
Green fluorescence images clearly indicate a significant amount of GFP
expression in the HSVl/Vero cells but almost none in the EGCG-ester-HSVl/Vero cells
as indicated by the yellow arrow in figure 21(C). In addition, the lysosome stain
demonstrates lysosome activation in the HSVl/vero cells but not in the EGC-esterHSVl/vero cells, as indicated by the yellow arrow in figure 21(D). Since there is a strong
background in the fluorescence stains, black and white images (figures 24-26) were also
obtained to further illustrate the phenomenon observed in figure 21.
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Figure 21. Fluorescence Microscopy Data of 8hrs Post-Infection for HSV1 Infected Vero Cells and EGCG-ester
Treated Infected Vero Cells (A) Phase Contrast of HSVl/Vero; (A’) Phase Contrast off EGCG-ester-HSVl/Vero;
(B) DAPI stain of HSVl/Vero; (B’) DAPI stain of EGCG-ester-HSVl/Vero; (C) GFP of HSVl/Vero; (C’) GFP of
EGCG-ester-HSVl/Vero; (D) Lysosome stain of HSVl/Vero; (D’) Lysosome stain of EGCG-ester-HSVl/Vero;
(E) GFP+DAPI of HSVl/Vero; (E’) GFP+DAPI of EGCG-ester-HSVl/Vero; (F) GFP+DAPI+lysosome of
HSVl/Vero; F) GFP+DAPI+lysosome of EGCG-ester-HSVl/Vero.
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In the 10 hours post infection images, the cell morphology is significantly
changed in HSVl/Vero cells, even more so than 8 hours post infection. EGCG-esterHSVl/Vero cells look very similar to the cells only image. In the HSVl/Vero cells DAPI
stain, there is even further granulation and demargination in the cell nucleus. Green
fluorescence particles are also observed in the HSVl/Vero cells only. Lysosome stain
showed no significant activation for HSVl/Vero cells in the 10 hours post infection. On
the contrary, EGCG-ester-HSVl/Vero cells demonstrate similar results to the 8 hours
post infection in all of the fluorescence images.
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Figure 22. Fluorescence Microscopy Data of lOhrs Post- Infection for HSV1 Infected Vero Cells and EGCGester Treated Infected Vero Cells (A) Phase Contrast of HSVl/Vero; (A’) Phase Contrast of EGCG-esterHSVl/Vero; (B) DAPI stain of HSVl/Vero; (BJ) DAPI stain of EGCG-ester-HSVl/Vero; (C) GFP of
HSVl/Vero; (C’) GFP of EGCG-ester-HSVl/Vero; (D) Lysosome stain of HSVl/Vero; (D’) Lysosome stain of
EGCG-ester-HSVl/Vero; (E) GFP+DAPI of HSVl/Vero; (E’) GFP+DAPI of EGCG-ester-HSVl/Vero; (F)
GFP+DAPI+lysosome of HSVl/Vero; F) GFP+DAPI+lysosome of EGCG-ester-HSVl/Vero.
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In the 12 hours post infection experiment, the cell morphology remained similar
to cells at 8 and 10 hrs post infection. More granulation and demargination are seen at
this stage of infection in the HSVl/Vero cells when stained with DAPI. Green
fluorescence particles are also observed. No lysosome activation was observed. EGCGester HSVl/Vero cells shows similar results to the 8 and 10 hours post infection cells in
all the fluorescence images as well as similar to the cells only images.
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Figure 23. Fluorescence Microscopy Data of 12hrs Post- Infection for HSV1 Infected Vero Cells and EGCGester Treated Infected Vero Cells (A) Phase Contrast of HSVl/Vero; (A’) Phase Contrast of EGCG-esterHSVl/Vero; (B) DAPI stain of HSVl/Vero; (B’) DAPI stain of EGCG-ester-HSVl/Vero; (C) GFP of
HSVl/Vero; (C’) GFP of EGCG-ester-HSVl/Vero; (D) Lysosome stain of HSVl/Vero; (D’) Lysosome stain of
EGCG-ester-HSVl/Vero; (E) GFP+DAPI of HSVl/Vero; (E’) GFP+DAPI of EGCG-ester-HSVl/Vero; (F)
GFP+DAPI+lysosome of HSVl/Vero; F) GFP+DAPI+lysosome of EGCG-ester-HSVl/Vero.
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In summary, when comparing and contrasting the results of the fluorescence
microscopy, it is clear to the observer the differences between HSVl/Vero cells and
75^iM EGCG-ester HSVl/Vero cells. There are visible viral particles in the cells infected
with HSV 1 and almost no virions in the cells infected with EGCG-ester -HSV1.
The nucleus of the cells is also very different. In the cells infected with HSV1, the margin
of cells is lost, and there is granulation of the chromosomes. In the cells infected EGCGester-HSVl, the nucleus of the cells were not affected. The comparison of GFP at 8, 10
and 12 hours post infection as well as the comparison of DAPI and lysosome stain at 8,10
and 12 hours post infection in black and white images are shown in figure 18.
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Figure 24. Fluorescence Microscopy Data of GFP expression at 8-12 hrs Post-Infection for HSV1 Infected Vero
Cells and EGCG-ester Treated Infected Vero Cells (A) 8hrs HSVl/Vero; (A’) 8hrs EGCG-ester-HSVl/Vero; (B)
lOhrs HSVl/Vero; (B’) lOhrs EGCG-ester-HSVl/Vero; (C) 12hrs HSVl/Vero; (C’) lOhrs EGCG-esterHSVl/Vero.
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Figure 25. Fluorescence Microscopy Data with DAPI Stain at 8-10 hrs Post-Infection for HSV1 Infected Vero
Cells and EGCG-ester Treated Infected Vero Cells (A) 8hrs HSVl/Vero; (A’) 8hrs EGCG-ester-HSVl/Vero; (B)
lOhrs HSVl/Vero; (B’) lOhrs EGCG-ester-HSVl/Vero.
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Figure 26. Fluorescence Microscopy Data with Lysosome Stain at 8-10 hrs Post-Infection for HSV1 Infected
Vero Cells and EGCG-ester Treated Infected Vero Cells (A) 8hrs HSVl/Vero; (A’) 8hrs EGCG-esterHSVl/Vero; (B) lOhrs HSVl/Vero; (B’) lOhrs EGCG-ester-HSVl/Vero.

Green fluorescence particles are seen from 8 to 12 hours post infection in the
HSVl/Vero cells (figure 24). The amount of nuclear granulation and demargination are
increased from 8 to 10 hours post infection in the HSVl/Vero cells as seen in figure 25.
In figure 26, it is clearly indicated that the lysosome activation can be seen at 8 hours but
decreases at 10 hours post infection in HSVl/Vero cells. These results correlate well with
reported events in HSVl/Vero cells lytic infection34. None o f this was observed in the
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EGCG-ester HSVl/Vero cells indicating that EGCG-ester at 75 pM is able to inhibit
HSV1 infections.

8. Molecular Mechanisms of EGCG-ester on HSVl/Vero Cells
The results of each experiment performed indicate that EGCG-ester is able to
inhibit HSV 1 viral production and no significant viral biosynthesis is observed in EGCGester HSVl/Vero cells. In order to understand the molecular mechanism of EGCG-ester
inhibiton on HSVl/Vero cells, genome-specific primers from HSV1 genome were
designed as seen in table 5.

Primer Design For PCR
Nucleotide sequence (5’ to 3’)
Primers
F. AG ACGT CCGGAA AC A ACCCT AC A A
gDl
gD2
gBl
gB2
gB3
GFP1
GFP2
VP11/12
VP11/12

R.ACACAATTCCGCAAATGACCAGGG
F. TTGTTTGTCGTCATAGTGGGCCTC
R. TGGATCGACGGTATGTGCCAGITT
F. AGArrCTGCGGTACrGCGArCACT
RACGGAACACAAACAAGCACGGATG
F. AGCTGATTATCGCCACCACACrCT
R TGGCGTTGArCTTGTCGATCACCT
F. ATT CT CCTCCGACGCC AT ATCC ACCTT
R. AG A A AGCCCCC ATT GGCC AGGT AGT
F.GT CAAAGCTT AAGATGGT GAGC A AGG
R. CTT GA AGCTTCTT GTAC AGCT CGTCC
F. TGACCCTGAAGTTCATCTGCACCA
R. AACTCCAGCAGGACCATGTGAr
F. ACCAAGCCTTGATGCrCAACTCCA
R. ACAACACGGTTCCCGAGAGTTTGA
F. ACCAAGCCTTGATGCrCAACTCCA
R. ACACAACACGGTTCCCGAGAGTTT

Tm
64.6
64.6
64.6
64.6
64.6
64.6
64.6
64.6
67.6
67.9
64.6
66.2
64.6
62.7
64.6
64.6
64.6
64.6

Amplicon
752
938
986
910
191
544
717
957
959

Table 5. Primers Used in Polymerase Chain Reaction for Analysis of HSV1/ Vero Cells DNA.

The primer sets were used to prime DNA isolated from HSVl/Vero and EGCGester HSVl/Vero cells. The PCR product was analyzed using 1% gel electrophoresis and
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the results are shown in figure 27. All the primers were able to prime the DNA samples
and the amplicons have the expected sizes.

Figure 27. Priming of HSVl/Vero Cells DNA with Different Designed Primers.

9. Sequencing of PCR products
The PCR products for each primer set 1-9 have been sequenced and analyzed
using NCBI homology search. The results indicated high homology to the reported HSV1
sequence as seen on figures 28-36. Therefore, the designed primers can be used to
successfully study the molecular mechanisms of inhibition o f EGCG-ester on HSVl/Vero
cells.
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Glycoprotein D- PrimerlF- 733bps
GTCATGCCATGCTCGGATGGGAGGCACTGTGCTATCCCCATCACGGTCATGGAGTACACCGAATGC
TCCTACAACAAGTCTCTGGGGGCCTGTCCCATCCGAACGCAGCCCCGCTGGAACTACTATGACAGC
TTCAGCGCCGTCAGCGAGGATAACCTGGGGTTCCTGATGCACGCCCCCGCGTTTGAGACCGCCGGC
ACGTACCTGCGGCTCGTGAAGATAAACGACTGGACGGAGATTACACAGTTTATCCTGGAGCACCGA
GCCAAGGGCTCCTGTAAGTACGCCCTCCCGCTGCGCATCCCCCCGTCAGCCTGCCTCTCCCCCCAGG
CCTACCAGCAGGGGGTGACGGTGGACAGCATCGGGATGCTGCCCCGCTTCATCCCCGAGAACCAGC
GCACCGTCGCCGTATACAGCTTGAAGATCGCCGGGTGGCACGGGCCCAAGGCCCCATACACGAGCA
CCCTGCTGCCCCCGGAGCTGTCCGAGACCCCCAACGCCACGCAGCCAGAACTCGCCCCGGAAGACC
CCGAGGATTCGGCCCTCTTGGAGGACCCCGTGGGGACGGTGGCGCCGCAAATCCCACCAAACTGGC
ACATCCCGTCGATCCAGGACGCCGCGACGCCTTACCATCCCCCGGCCACCCCGAACAACATGGGCC
TGATCGCCGGCGCGGTGGGCGGCAGTCTCCTGGCAGCCCTGGTCATTGGGGAAATTTTTTGTATATA
AAAAAA
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Figure 28. Blast Search Results for Retrieved Sequence of Glycoprotein D Primer IF.

Glycoprotein D- Primer 2F- 947bps
AGGCTGCGCGATATGCTTGGCGGATGCTCTCTCAGATGGCCGACCCCAATCGCTTTCGCGGCAAAG
ACCTTCCGGT CCT GG ACC AGCT GACCG ACCCTCCGGGGGT CCGGCGCGT GT ACC AC ATCC AGGCGG
GCCTACCGGACCCGTTCCAGCCCCCCAGCCTCCCGATCACGGTTTACTACGCCGTGTTGGAGCGCGC
CTGCCGCAGCGTGCTCCTAAACGCACCGTCGGGAGGCCCCCCCAGATTGTCCGGCGGGGGCCCTCC
GAAGGACGTTCCGGAAACAACCCTACAACCTGACCATCGCTTGGTTTCGGATGGGAGGCAACTGTG
CTATCCCCATCACGGTCATGGAGTACACCGAAATGCTCCTACAACAAGTCTCTGGGGGCCTGTCCCA
TCCGAAAACGGGCCCCGCGGGAAAAATAAAAAAAAAAATTTTCCGGGGCCGGAGGAAAAAAAACC
GGGGGTTTT AT AAAGGGGGGGGGGGTTGAAAAAAT ACGCCGGCACGTACCTGCGGTTCGTGGAAG
ATAAAAAGTGACGGAGATTAATTTTATTGGGCCGGCCGGGCCCGTAGTACGCCCTCCGCTGCGCAT
CCCCCCCGTCAGCCTTGCCTCTCCCCCCCAGGCCTAACAGCAAGGGGGGTGAACGGTGGGAACAGC
AATCGGAATGGCTGGCCCCGCTTTCAATCCCCCGAGAAAACCAAGCCGCAACCGGTCGCCCGGTAA
TTACAGGCTTGGAAAGGATCGCCGGGTAGACAACGGGGCCCCAAAGGCCCCATACAACGTAGTCA
CCCTTGGCTTGCCGCCCGGAGCTGTTCCGAGAACTTCTCAATGGCTCACGCGCAGCCGGGAAAGTTC
GTCTCCGGCAAGAACACGAGAGAATTCGTCCCATCATTGGAAGAGGCCTAGTGCGCTACGGTGTTG
’A T

r

ATCA TT AT CTr
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Figure 29. Blast Search Results for Retrieved Sequence of Glycoprotein D Primer 2F.

Glycoprotein B- Primer IF- 425 bps
CAGGCATCACACCATCACAGACCATCATCGTAGAGTACCGCCGTCCCCCAGCGTGCAGGCGGCGGC
CGCGTGGTAGAGCAGGCGGGGGGGCGTGGAGCGTGGCAGACCGCCATGGACGCGTGGACGCGCAT
CCGTGCGCGTTTTCCTCCATGTAGGGGAACCTGAAACTGGTAGCGGCCCGTAAGGCCGCCCGCCCA
GGAACAT GT GGGGGTT A AGC AT AGC AAGT ACT ACGGC AGTGCCGGGT AAC ACCGT GT GTTTC AGCG
CGGCAACTGGCGCAGCCTTGTGGGTAGCAAACACGCCGTGCCCGGCCTTTATTTTTGACGGACCCG
GCAGATCGTTCAAGCCGGACGCGGGCCGGGTTTAGTAGCGCGGCAGGGACCTCGGCGAGGAGACA
GGAAGCT CGCT AT C AG ACTATCCGGGT AATT
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Figure 30. Blast Search Results for Retrieved Sequence of Glycoprotein B Primer IF.
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Glycoprotein B- Primer 2F- 967 bps
TTCTCCTAACGGGTGCGCGGACTCGAGAGCGCCGCCCGGACTGCAGCCGCCGACCTCCGAAGTCGT
TACAGCAAGACGCGCGGCGAATATCTCACGTACGACTCCGACTGTCCGCTGTTGGCCATCGTCGAG
AGCGCCCCCGACGGCTGTATCGGCCCCCGGTCGGTCGTGGTCTACGACCGCGAAGTTTTTCTCGATC
CTCTACTCGGTCCTCCAGCACCTCGCCCCCAGGCTACCTGACGGGGGTTACGACGGGCCCCGTAGCC
CCGGCATTGCACAAGGCCCCCCCCTCGGGGGGGCCGCCGGGGGTTCGCCGTTAGGGTCCCTTTGGG
GGTGGAGGGGGGGGTTTGGGTTTTTCGGGTTTTTTGCCCATTTTCCCGTTACGGCTTGGGGTTGGGG
GCGGCCCCAGGGGGGGGGAGGGGGGGGGATTGGAAATTCCGCCGGCCCCCCCCCTTGTGGCCCCCC
CCCAAGGGGGGGGGGCGGGAAGGGGAAAAAAAAAAAAAAACCAAAAAAACCCGGGGCCCCCCCC
CCCCCCACCCGAAAAAAGCCAAATTGGTGGAGGGGGGGGGGCCCCCCTGGGGGGGGACCCCGTGG
GGGAAATTGGGGGGTAAAAAAACCCCTTTTATTTTCTTGGGGGGGGCCCCCCCCCCAGGGGGCCTG
GGGGGTCC AATTT AAGAAACCC AC AAAATTTTCCGT ACC GGCCC AAGGAT AC AA AAATTTACCGAG
GACCCCCGGGGGGGTTTTTTTAGAAAAAAAACCCCCCCCCCAAAAATTTCGAGGGCCCAAAGTGTA
AAAAAAAAACGCCCTGCCGTTTTTTACAGAATATTTTTCTTTGCCGAAACCTTAACTCCTCCAATTTT
TAAGGGGAGATTTTTTTAAAGACACGCCCCCTCTCTTCCTTTTTTCGAGGAGGGGGTAAATAGAACA
TAAGT AT CGCGCCC ATAAAA A AAA AG ATAG AAT A AAA AGG
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Figure 31. Blast Search Results for Retrieved Sequence of Glycoprotein B Primer 2F.

Glycoprotein B- Primer 3F- 156bps
CCACCAGACCGAGTACCCGCTCTCGCGCGTGACCTGGGGGACTGCATCGGCAAGGACGCCCGCGAC
GCCATGGACCGCATCTTCGCCCGCAGGTACAACGCGACGCACATCAAGGTGGGCCAGCCGCAGTAC
TACCTGGCC AATGGGGGCTTT CTT
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Figure 32. Blast Search Results for Retrieved Sequence of Glycoprotein B Primer 3F.

GFP- Primer IF- 714bps
GAGGCCGGATCACGGGTGTGCCATCCTGGTCGAGCTGGACGGCGACGTAACGGCCACAAGTTCAGC
GTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACC
GGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCC
GCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGG
AGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCG
ACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGG
CACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGG
CATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTA
CCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCA
GTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGC
CGCCGGGATCACTCTCGGCATGGACGAGCTGTACTGAAAACTCTCTTTGAGGAAA
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Figure 33. Blast Search Results for Retrieved Sequence of GFP Primer IF.

GFP- Primer 2F- 513bps
CGCCGCCGTCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCC
CGACCACAAGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCAC
CATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCT
GGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGC
T GG AGT AC AACT AC AAC AGCC AC AACGT CT AT AT CATGGCCG AC A AGC AG AAGAACGGC AT CAAG
GTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAG
AACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCC
CTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCTGCCGGGAGTTAA
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Figure 34. Blast Search Results for Retrieved Sequence of GFP 2F.
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VP11/12- Primer 1- 964bps
TCCGCG TG G G G G CG TCATCG TG G G G ACAG G G G G G CG GTG G TCCG ACAG AACG CTCCTG G CTG TCCA
CCGCGGCCCGCAGATACTCGTTGTTCAGGCTGTCGGTGGCCCAGACGCCGTACCCGGTGAGGGTCG
CG TTG ATG ATATACTG G G CG TG G TG ATG G ACG ATCG ACAG AACCTCCACCG TG GATACCACG G TAT
CCACG G TCCCG TACG TACCGCCG CTCCG CTTG CCG G TCTGCCACAG G TTG G CTAG GCACG TCAG G TG
G CCCAGGACGTCGCTGACCGCCGCCCTGAGCGCCATGCACTGCATGGAGCCGGTCGTGCCGCTGGA
ACCCCGGTCCAAATGGCGCGCGAACGTTTCCGCGGGCCCCTTCCGGGCTGCCGCCGAAGCGGAAGG
AACCG G G CAATTG G AG G G ACTCAG CCG G TG ACATACG TG CTTGTCCG TCG TCAACG G CATCCAG G A
GGCCCACCGGTACAGCACGGAAACGTAGGCCAGGAGCTCCGTTAAGCCGCATTGCGGTGTCGGTCC
TG G G ACG TTTTG GG CCCCCCGG G G CG CATAAG G AACATG TACTG CTG AATCCAATG G AG G G G CG TC
GCGC AG CCG G CCCA CG G TG G CG G CTTA TTTG G G CCCCCG CG CCCCCG CCTTTT AAACGGGGTGCCG
CGCCAAGCCACTTTTGGGGCCGGGTTGGCCCGCAACAACCACGTGAAAGGCTGGGGCTCCGCAGTC
GCCCACGGGGTCCTTCGGGAAACGTCAAGGCCGGCTGGGCCACAACCGTCTGCAGGTACTTCAAGT
ACTG CGTG G AGG ATG G CG CG CTCAAACTG G G CCG CTCTG G TCAG CTCCACCTTCG CCCAG CG CTG G
G TG TCG G TCTG AAG CG TA CTG CCG G ATG TA CTCG TTAGTGCAGGTCG CTTGGCGAG CCCG T CACG AT
C T A G A C T A T C G T G G G G A G A G A G T G T G T A G T A T A T A T A A ____________________________________________

Distribution of 62 Blast Hits on the Query Sequence
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Mouse over to see the defline, click to show alignments

Color key for alignment scores

Sequences producing significant alignments;
Description

Accession

q 1222478320IF1593289.1
q 119445361X14112,1
q 1290766081IGU734772.1
q 1290766003IGU734771.1
q I330056IM15621.1
q 1114318788100889502,1
q 1154744672IEU029143.1
q 11547446701EUO29142.1
q 1154744668IEU029141.1
q 11547446661EU029140,1
q 1154744664IEU029139.1
q 1154744662IEU029138.1
q 1154744660IEU029137.1
a 1161789583IEU281624.1
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Figure 35. Blast Search Results for Retrieved Sequence of VP11/12 Primer IF
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VP11/12- Primer 2- 964bps
TTCAGCTGGGGGCGTCATCGTGCGGACAGGGGGGCGGTGGTCCGACAGAAACGCTCCTGGCTGTCC
ACCGCGGCCCGCAGATACTCGTTGTTCAGGCTGTCGGTGGCCCAGACGCCGTACCCGGTGAGGGTC
GCGTTGATGATATACTGGGCGTGGTGATGGACGATCGACAGAACCTCCACCGTGGATACCACGGTA
TCCACGGTCCCGTACGTACCGCCGCTCCGCTTGCCGGTCTGCCACAGGTTGGCTAGGCACGTCAGGT
GGCCCAGGACGTCGCTGACCGCCGCCCTGAGCGCCATGCACTGCATGGAGCCGGTCGTGCCGCTGG
GACCCCGGTCCAGATGGGGGCGCGAACGTTTCCGGGGGGCCCCTCCGGCCTGCCGCCGAGCGGAAG
G A A C C G G G C A A T T G G A G G G A C T C A G C C G G G G A C A T A C G T G C TT T G T C C G T C G T C C A C A G C A T C A G G
GACGCCCACGGTTACAGCACGGAAACGTAGCCCAGGACCTCTTTGACCCGCAGTGCGGTTTCGGTC
CTGGGGCGACTTGGTCCCCCCGGGCCCCATAAGGAACATGTACTGCTGAATCCAATGGAAGGGCGT
CGGCCAGCCCGGCCAGGGTGGCGGCTAATTTGGGCCGCCGGCGCCCCCGCTTTTGAACGGGGGTGC
GCGCCAGCGTTTTTGGGGCCGGGGGTGGGCCCGCGCCACCACGTGAAGGCCGGGGTCCGCAGTCCC
CCCACGGGGTCTTGGGGAATGTCAGGGCGGTGGGAACCACCGTTCGGCGGTACTTTCCGGAACGGG
CGTGAAGGATGGCGCGGCTCAAACTGGACCGCGGGGCAGTCTCCACTTTCGCCCAAGCGCCTGGGT
GTGCGGCCGAAAGCATATGCCGGAATGTACTCGTAGTGACGGTTCGCTGGCGAGCCGGTCACGATC
A A T C T C T C G G A G A C G T G G T G T G A T A G T A T A T A A _______________________________________________

Distribution o f 76 Blast Hite on the Query Sequence
Mouse over to see the defline, click to show a l i g n m

&

e n t s _____

Color key for alignment scores

Sequences producing significant alignments:
Accession

oil 22247832810593289.1
q 119445361X14112.1
q I29O7660B1IGU734772.1
q 11143187681D0889502.1
q 1290766003IGU734771.1
la. 13300561M15621.1
!q 11547446741EU029144.1
q 1154744672IEUQ29143.1
q 1154744670IEU029142.1
iq 115474466BI EU029141.1
q 11547446661EÜ029140.1
q 1154744664IEUÛ29139.1
q 11547446621EUQ29138,1
q 11547446601EU029137.1
la 1161789583IEU281624.1
FUjure 36. Blast Search
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Human herpesvirus 1 transgenic strain 17, complete genor 1144
1144
Human herpesvirus 1 complete genome
1139
Human herpesvirus 1 strain H129, complete genome
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Human herpesvirus 1 strain F, complete genome
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Human herpesvirus 2 isolate subject ID GW13903 specime __728
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Human herpesvirus 2 strain 186 UL46 (UL46) gene, comph 72i
Results for Retrieved Sequence of VP11/12 Primer 2F
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10. Comparison of Amplicons of Glycoprotein D, GFP, and VP11/12 in HSVl/Vero
Cells and EGCG-ester-HSVl/Vero Cells Using PCR-Based Assay.
DNA extracted from HSVl/Vero cells and EGCG-ester HSVl/Vero cells was
purified and isolated and the amount and purity was determined by Nanodrop
spectrophotometer ND1000 as shown in figure 39. Since the concentration of DNA in
each samples is similar in quantity, 1pL was used from each sample with constant
amount of primer for glycoprotein D to do a comparatively PCR-based assay. The results
are shown in figure 37. By using a Kodak Image analyzer 440CF, the band intensity of
each experiment was measured (figure 38). It is indicated that 75pM EGCG-ester
HSVl/Vero intensity of PCR product was less than the intensity of HSVl/vero cells.
Further experiment was carried out using primers for glycoprotein D, GFP and V P11/12
to perform PCR-based assay. The results shown in figure 40 demonstrate that when
HSV1 is treated with 75 pM EGCG, the DNA band intensity is decreased. When HSV1
is treated with75 pM EGCG-ester the DNA band intensity is further decreased. This
implies that fewer HSV1 particles were able to infect Vero cells when treated with EGCG
and even more when treated with EGCG-ester as compared to Vero cells infected with
HSV1 only. However, in order to have a quantitative measure, further analyses needed to
be carried out by using Real Time PCR.
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Band intensity:
Control: 445.92, 588.24, 541.73

avg: 525.29
75uM: 353.87, 438.47, 407.82

avg: 400.05
Figure 38. Band Intensities from Kodak
Image Station

Figure 37. Polymerase Chain Reaction Priming Glycoprotein D of HSV. Lane (3)HSVl/Vero; Lane(5) 75pM
EGCG-ester-HSVl/Vero; Lane (7) Vero Cells Only; Lane (8) No DNA Negative Control.

Nanodrop:
Control: 566.4 ng/^iL
75|aM EGCG-ester: 560.1 ng/^iL
Cells only: 562.8 ng/^iL
Figure 39. DNA Concentrations of DNA Extraction
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Figure 40. (A)Polymerase Chain Reaction Priming Glycoprotein D of HSV1. Lane (2)HSVl/Vero; Lane(3)
75pM EGCG-HSVl/Vero; Lane (4) 75pM EGCG-ester-HSVl/Vero; Lane (5)Vero Cells only; Lane (6) No DNA
negative control. (B)Polymerase Chain Reaction Priming GFP tag in HSV1UL46. Lane (2)HSV1/Vero; Lane(3)
75pM EGCG-HSVl/Vero; Lane (4) 75pM EGCG-ester-HSVl/Vero; Lane (5)Vero Cells only; Lane (6) No DNA
Negative Control. (C)Polymerase Chain Reaction Priming of VP11/12 Tegument Protein of HSV1. Lane
(2)HSVl/Vero; Lane(3) 75pM EGCG-HSVl/Vero; Lane (4) 75pM EGCG-ester-HSVl/Vero; Lane (5)Vero Cells
only; Lane (6) No DNA Negative Control.
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11. Quantitative Study of Glycoprotein D in HSV1/ Vero Cells and EGCG-esterHSVl/Vero Cells by Using Real Time PCR.
The previous experiment suggested that the amplification of Glycoprotein D is
less in EGCG-ester-HSVl/Vero cells compared to HSVl/Vero cells, therefore it is
important to carry out quantitative study of Glycoprotein by using Real time PCR.
Special primers were designed for this study as shown in table 6. The process of real time
PCR works by collecting fluorescence data at the end o f each cycle of the reaction. The
SYBR green dye used in the experiment binds to the double stranded PCR product
causing the PCR product to fluoresce. As the reaction continues the instrument recalls the
threshold for each sample. The threshold cycle (Ct) is the critical cycle at which the first
significance increase in fluorescence is detected. Once the PCR cycles ended, the data
were collected and the Ct values for each of the samples were analyzed and the relative
quantity (RQ) of fluorescence was reported. The standard for comparing Ct values is that
a difference in one Ct is equivalent to a two-fold difference in the amount of DNA.
100ng/pL of DNA was used for all samples; cells only, HSVl/Vero, and EGCG-ester
HSVl/Vero. The results are shown in figures 41 and 42.

Primer Desi sn For RT-PCR
Primers Nucleotide sequence (5’ to 3’)
F. CAACCCTACAACCTGACCATC
gDl
R. TTGTAGGAGCATTCGGTGTAC

Tm
62.6
60.6

Amplicon
100bps
100bps

Table 6. Real time PCR Primers for Priming Glycoprotein D on HSV1
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ct

Figure 41. Real Time PCR Data of HSV1 Glycoprotein D.

Figure 42. Relative Quantity of HSV1 Glycoprotein D Amplification in HSVl/Vero, EGCG-HSVl/Vero and
EGCG-ester-HSV 1/Vero Cells.
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Percentage
100%

pos control

EGCG

EGCG-ester

Figure 43. Percentage of HSV1/ Vero Infection, EGCG-HSV1 /Vero and EGCG-ester-HSVl/Vero Cells.

The results show a 32-fold difference in the amount of glycoprotein D of EGCGHSVl/Vero to HSVl/Vero and a 256-fold difference from HSVl/vero to EGCG-ester
HSV1/ Vero. Our results suggest that EGCG inhibits HSV1 95% and EGCG-ester
inhibits HSV1 99.46%(fig 43). Its mode of action seems to be by interfering with the
virion envelope glycoproteins or by interfering with viral compounds for viral adsorption
and cell entry34,43. Apparently, inhibition appears to occur during adsorption but not after
penetration of the virus (figure 44). By using a green fluorescent protein tag, we were
able to confirm that GFP expression is greatly decreased in treated virus compared to
control virus.
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Figure 44. Schematic Representation of Possible Mode of Action of EGCG-ester on HSV1.

Conclusions
The effect of EGCG and EGCG-ester on HSV1 and Vero cells have been studied
using different approaches to establish the concentrations that do not affect the host cells
but efficiently inhibits the virus. First, in the cell cytotoxicity assay, as the concentration
of polyphenols increased, cell morphology did change a little. This was seen when
polyphenols were added at the same time as cells were plated. On the other hand, when
the polyphenols were added for 1 hr after the cells had already been plated for 24hrs, and
then consequently removed, cell morphology did not seem to be affected. Cell
proliferation was also not significantly impaired as the concentrations of polyphenols
increased. In addition, the percentage of cell death did not change much when cells were
treated with EGCG-ester compared to control.
The maximum nontoxic concentration was identified to be 75pM for both EGCG
and EGCG-ester and these concentrations were then used to study their effect on HSV1
viral production. In the plaque assay, the results showed that when the virus is previously
treated with 50pM EGCG, there is a 10-fold decrease in plaque formation. On the other
hand, when HSV is treated with EGCG-ester at a concentration of 50pM and above, there
are no plaques observed. Different concentrations of EGCG-ester were then used to
determine the minimum HSV 1 inhibitory concentration. The results suggested that at a
concentration of 50pM and above, EGCG-ester completely inhibits PFU formation.
In the fluorometer experiment, GFP expression is much lower at 75pM-EGCGester HSV1/ Vero cells compared to HSVl/Vero cells. Thus, expression of GFP as part of
viral biosynthesis is decreased when HSV 1 is treated with EGCG-ester. In addition, the
fluorescent microscopy analyses showed remarkable results with both the GFP and DAPI

68

stain. GFP expression was reduced in the 75pM-EGCG-ester HSV1/ Vero cells as
compared to HSVl/Vero cells. Also, when evaluating the morphology of the nuclei of the
HSV1/ Vero cells to the EGCG-ester-HSVl/Vero cells several differences are seen. The
nuclei of the HSV1/ Vero cells lose their margins during infection, and there is major
granulation of the chromosomes. On the contrary, the nuclei of the EGCG-esterHSVl/Vero cells keep their integrity throughout infection.
Lastly, the PCR based of DNA of assay of glycoprotein D of HSVl/Vero showed
higher band intensity as compared to EGCG-ester-HSVl/Vero cells. This infers that there
was more viral DNA in the cells infected with HSVl/Vero as compared to 75pM EGCGester-HS V 1/V ero.
Also, the real time PCR- based assay indicated that there is a 32-fold difference in the
amount of DNA of glycoprotein D in EGCG-HSV1/Vero cells compared to the DNA of
HSVl/Vero cells and a 256-fold difference from HSVl/Vero cells to EGCG-ester HSV1/
Vero cells. Our results suggest that EGCG-ester inhibits HSV1 to a great extent and is
more effective against HSV 1 when compared to EGCG alone.
In summary, both EGCG and EGCG-ester can inhibit HSV1, but EGCG-ester has
proven to be more potent compared to EGCG in inhibiting the action against HSV 1
infections in vitro. Contrary to EGCG, EGCG-ester is a stable compound and is also
stable at vaginal pH and would be an ideal candidate for a topical application. An EGCGester topical application against HSV1 and possibly HSV2 would benefit millions of
people every year. Furthermore, by being able to stop the spread o f the disease enables us
to possibly stop the link between HSV and HIV. Although further studies need to be
conducted in order to completely understand the mode of action of EGCG-ester in
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humans the results obtained in this study are very promising. The use of natural products
may improve the lives of many and thus give patients hope for a better and healthier
future.
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Future Studies
The results of this study suggested that EGCG-ester is able to effectively inhibit
HSV1 in Vero cells (Green monkey kidney cells). Some preliminary results were also
obtained by using human A549 cells. Future studies should be carried out to understand
the molecular mechanism of EGCG-ester on HSV1. EGCG-ester can be potentially used
as a novel approach to inhibit HSV1.
Using the human cell line A549, the same studies should be carried out to
determine the optimal concentration of EGCG-ester on cell cytotoxicity. HSV1 inhibition
will also be studied by performing plaque assay, fluorometry study, fluorescence
microscopy, PCR and real time PCR.
In addition, further studies need to be conducted in order to understand the exact
mechanism of EGCG-ester in inhibiting HSV1. EGCG- ester seems to be inhibiting
HSV1 cell entry by either binding to the virion glycoproteins or preventing them from
participating in viral adsorption and penetration or by interfering with the virus itself,
maybe by damaging its envelope and thus disabling the virus from getting into contact
with the host cell.
Lastly, all the primers designed to target different regions of H SV 1 genome
should also be used in real time PCR study. Additional primers should also be designed
for genome regions involved in viral replication. Furthermore, reverse transcriptase PCR
can be used in different steps of viral infection to look at the expression of genes involved
in viral replication, which will help elucidate the molecular mechanisms of EGCG-ester.
The ultimate goal is to use an animal model to study the effect o f EGCG-ester on
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HSV1 infected animals. This will allow us to further develop a topical application for
human usage.
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Appendix
1. Cytotoxicity Study of EGCG/A549 cells and EGCG-ester/A549 cells with
Removing the Polyphenols (24hrs):
The effect of different concentrations of EGCG and EGCG-ester on A549 cells
was observed at 24 hours. In this study, A549 cells were plated first for 24 hours and then
different concentrations of EGCG and EGCG-ester (12.5, 25, 50, 75, 100pM) were added
to the cells and allowed to adsorb for 1 hour. EGCG and EGCG-ester was then aspirated,
and cells were observed 24 hours later. The results are shown in figures 1 and 2. The
results suggest that when EGCG is added to A549 cells, the maximum nontoxic
concentration was observed to be 25pM. At the concentration o f 50 to lOOpM, cell
morphology is affected to a certain extent. In the presence o f EGCG-ester the maximum
nontoxic concentration was evaluated to be 12.5pM.

Figure 1. Microscopic Observation (100X) of Cytotoxicity Study of A549 Cells Treated with Different
Concentrations of EGCG (A) OpM; (B) 12.5pM; (C) 25pM; (D) 50pM; (E) 75pM; (F) lOOpM.
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Figure 2. Microscopic Observation (100X) of Cytotoxicity Study of A549cells Treated with Different
Concentrations of EGCG-ester (A) OpM; (B) 12.5pM; (C) 25pM; (D) 50pM; (E) 75pM; (F) lOOpM.

2. Fluorescence Microscopy Observation of HSV1/A549 cells and EGCG-esterHSV1/A549 Cells
The lytic cycle of HSV1/ A549 cells was observed at 8 hours post-infection to
study the molecular changes within the infected cells. HSV1/A549 cells were used as
positive controls. 75 pM EGCG-ester-HSVl/A549 cells were also monitored and
compared to control. GFP-HSV1, DAPI stained nucleus and lysosome stain were used to
identify cytophatic effects on A549 cells.
Phase contrast image for HSV1/A549 cells did not show a difference in cell
morphology, but when staining the HSV1/A549 cells with DAPI stain, there is an
obvious difference in the cell nucleus compared to the EGCG-ester-HSVl/A549 cells.
Significant granulation as well as demargination is only seen in the HSV1/A549 cells,
demonstrating a normal occurrence of viral infection as indicated by the yellow arrow in
figure (3). EGCG-ester- HSV1/A549 cells still maintained their nuclear integrity.
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Green fluorescence images clearly indicate a significant amount o f GFP
expression in the HSV1/A549 cells but almost none in the EGCG-ester-HSVl/A549 cells
as indicated by the yellow arrow in figure 3(C). In addition, the lysosome stain
demonstrates lysosomal activation in the HSV1/A549 cells but not in the EGC-esterHSV1/A549 cells, as indicated by the yellow arrow in figure 3(D). Further experiments
have to be carried out to better understand the effect of EGCG and EGCG ester on
HSV1/A549 cells.
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Figure 3. Fluorescence Microscopic Observations of A549 Cells Monolayer (400x). (A) Phase Contrast; (B)
DAPI stain; (C) GFP; (D) Lysosome stain (E) GFP+DAPI; (F) GFP+DAPI+Lysosome.
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